(SAN) Sanofi - Ratings and Ratios

Sanofi SA (PA:SAN), a global healthcare leader, specializes in the research, development, and distribution of innovative therapeutic solutions. The company operates across the United States, Europe, and international markets, focusing on key areas such as immunology, inflammation, rare diseases, neurology, oncology, and vaccines. Sanofis vaccine portfolio includes poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines, as well as respiratory syncytial virus protection and hexavalent combination vaccines. Additionally, the company offers influenza, booster, meningitis, and travel/endemic vaccines, including hepatitis A, typhoid, yellow fever, and rabies vaccines. Sanofi has established multiple strategic collaborations to advance its pipeline: with Exscientia for up to 15 novel small-molecule therapies in oncology and immunology; ABL Bio, Inc. for ABL301, targeting alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences for pivotal studies and clinical development programs. Further collaborations include partnerships with IGM Biosciences, Inc. for IgM antibody development; Kymera Therapeutics, Inc. for protein degrader therapies targeting IRAK4; Nurix Therapeutics, Inc. for targeted protein degradation therapies; Denali Therapeutics Inc. for systemic inflammatory diseases like ulcerative colitis; and Adagene Inc. for antibody-based therapies. Sanofi also collaborates with Scribe Therapeutics Inc. on genome editing technologies and has a co-promotion agreement with Provention Bio, Inc. for teplizumab. Formerly known as Sanofi-Aventis, the company adopted its current name in May 2011. Headquartered in Paris, France, Sanofi was incorporated in 1994 and is listed on the Euronext Paris under the ticker symbol SAN. Web URL: https://www.sanofi.com.

Sanofis strategic focus on innovation and partnerships positions it as a key player in the pharmaceutical industry. The companys diverse product portfolio and extensive collaboration network underscore its commitment to addressing unmet medical needs. With a strong emphasis on research and development, Sanofi continues to expand its offerings in critical therapeutic areas, ensuring its position as a leader in global healthcare.

3-Month Forecast:

Based on and , Sanofi SA (PA:SAN) is expected to experience moderate volatility in the near term. The stocks price is currently below its 20-day and 50-day moving averages (SMA), suggesting potential bearish sentiment. However, the forward P/E ratio of 11.55 indicates expectations of earnings growth. The average trading volume of 2.45M shares suggests liquidity, while the ATR of 2.63 reflects moderate price fluctuations. Support levels are likely to be tested near the 200-day SMA of 98.57, with resistance at the 50-day SMA of 102.17. The companys fundamental strength, evidenced by a market cap of 121.77B EUR and a P/B ratio of 1.51, suggests stability. The recent collaborations and partnerships are expected to positively impact the stocks performance, driven by potential pipeline advancements and increased investor confidence.